Sanofi SA (SNY) has released an update.
Sanofi SA reports a robust first quarter with a 7% sales growth, underpinned by successful product launches and a strong showing from Dupixent, which is on track for projected annual sales. The company’s consumer healthcare division also saw a 9% increase, partly due to the Qunol acquisition. Despite these strong sales figures, Sanofi’s business earnings per share experienced a decline, but the company maintains its full-year financial guidance.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
